Some previous reports assessed the safety of anti-TNF treatment for elderly patients with IBD and demonstrated that older age was the only independent factor for SAEs, including infection, malignancy, and cardiovascular and death events23–25,31. This evidence concerns the gene TNF and inflammatory bowel disease.